Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:55:01 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:BCLI from 2023-04-27 to 2024-04-26 - 102 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-16 18:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
2024-04-11 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
2024-04-10 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's(TM) Phase 3 Clinical Trial in ALS
2024-04-09 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
2024-04-08 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Provide Update on NurOwn Program
2024-04-01 08:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
2024-02-27 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn(TM) Trial Design at MDA Clinical and Scientific Conference
2024-02-23 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(TM) in ALS
2024-02-13 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum
2024-01-02 12:04U:BCLINews ReleaseBCLI DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
2023-12-29 18:34U:BCLINews ReleaseBCLI FINAL DEADLINE ALERT: ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Initiated by the Firm - BCLI
2023-12-27 16:06U:BCLINews ReleaseROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-26 15:03U:BCLINews ReleaseROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-26 07:30U:BCLINews ReleaseBrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments
2023-12-25 10:07U:BCLINews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-24 10:06U:BCLINews ReleaseROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-23 09:03U:BCLINews ReleaseROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-22 21:03U:BCLINews ReleaseROSEN, A LONGSTANDING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-20 09:00U:BCLINews ReleaseBrainStorm Issues 2023 Letter to Shareholders
2023-12-17 16:00U:BCLINews ReleaseROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-11 06:52U:BCLINews ReleaseSHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-11 06:32U:BCLINews ReleaseSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $500,000 to Contact the Firm
2023-12-11 00:01U:BCLINews ReleaseROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-10 21:32U:BCLINews ReleaseSHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-10 09:16U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - ‚  BCLI
2023-12-10 08:47U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-09 21:03U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - ‚  BCLI
2023-12-09 19:01U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of ‚  January 2, 2024 in ‚  Brainstorm Cell Lawsuit - ‚  BCLI
2023-12-09 03:32U:BCLINews ReleaseNATIONALLY RANKED ROSEN LAW FIRM Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-08 11:31U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - BCLI
2023-12-08 11:23U:BCLINews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
2023-12-08 09:01U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - ‚  BCLI
2023-12-08 08:47U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-08 08:17U:BCLINews ReleaseINVESTOR ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights - ‚  BCLI
2023-12-07 22:32U:BCLINews ReleaseINVESTOR ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights ¢ € “ ‚  BCLI
2023-12-07 11:16U:BCLINews ReleaseINVESTOR ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights - ‚  BCLI
2023-12-07 09:47U:BCLINews ReleaseSHAREHOLDER ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights - ‚  BCLI
2023-12-07 09:01U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of ‚  January 2, 2024 in ‚  Brainstorm Cell Lawsuit - ‚  BCLI
2023-12-07 08:47U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-07 08:40U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn ‚ ® in ALS
2023-12-06 18:02U:BCLINews ReleaseSHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop ¢ € “ Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-06 12:06U:BCLINews ReleaseSHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-06 09:08U:BCLINews ReleaseINVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-06 08:49U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-05 20:03U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ‚  BCLI
2023-12-05 12:36U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ‚  BCLI
2023-12-05 09:08U:BCLINews ReleaseINVESTOR ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights - ‚  BCLI
2023-12-05 08:49U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-05 03:31U:BCLINews ReleaseROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-04 21:31U:BCLINews ReleaseINVESTOR ALERT: Contact Levi & ‚  Korsinsky Before ‚  January 2, 2024 to Discuss Your Rights - ‚  BCLI
2023-12-04 13:32U:BCLINews ReleaseSHAREHOLDER ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - ‚  BCLI
2023-12-04 08:29U:BCLINews ReleaseIMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm
2023-12-04 05:45U:BCLINews ReleaseSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Brainstorm Cell Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: BCLI)
2023-12-03 16:02U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ‚  BCLI
2023-12-03 09:34U:BCLINews ReleaseSHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-03 08:48U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-12-03 08:31U:BCLINews ReleaseINVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-03 07:31U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ‚  BCLI
2023-12-03 06:42U:BCLINews ReleaseSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses In Excess of $500,000 to Contact the Firm
2023-12-03 00:01U:BCLINews ReleaseROSEN, SKILLED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-12-02 19:04U:BCLINews ReleaseINVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-02 11:10U:BCLINews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI
2023-12-01 16:16U:BCLINews ReleaseINVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop ¢ € “ Levi & Korsinsky Pursuing Class Action Lawsuit
2023-12-01 09:01U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline
2023-12-01 08:48U:BCLINews ReleaseBCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Brainstorm Cell Therapeutics Inc. Investors to Contact the Firm to Lead Class Action Lawsuit!
2023-11-30 17:02U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline ¢ € “ ‚  BCLI
2023-11-30 13:47U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of ‚  January 2, 2024 in ‚  Brainstorm Cell Lawsuit - ‚  BCLI
2023-11-30 12:47U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Notifies Brainstorm Cell Therapeutics Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ‚  BCLI
2023-11-30 09:01U:BCLINews ReleaseINVESTOR ALERT: Levi & ‚  Korsinsky Reminds Brainstorm Cell Therapeutics Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ‚  January 2, 2024 - ‚  BCLI
2023-11-29 03:01U:BCLINews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-24 19:00U:BCLINews ReleaseBCLI NOTICE: ROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BCLI
2023-11-22 22:08U:BCLINews ReleaseTOP RANKED ROSEN LAW FIRM Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BCLI
2023-11-20 08:10U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn ‚ ® in ALS
2023-11-19 19:01U:BCLINews ReleaseROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
2023-11-18 16:01U:BCLINews ReleaseROSEN, THE FIRST FILING FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm - BCLI
2023-11-17 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
2023-11-15 23:00U:BCLINews ReleaseROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-14 07:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update
2023-11-12 23:01U:BCLINews ReleaseROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-09 21:16U:BCLINews ReleaseROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-07 06:00U:BCLINews ReleaseBrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate Update
2023-11-06 00:01U:BCLINews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-04 22:31U:BCLINews ReleaseROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-11-04 01:01U:BCLINews ReleaseROSEN, SKILLED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of 100k to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLI
2023-10-24 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn ‚ ® for the Treatment of ALS
2023-10-18 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
2023-10-09 01:31U:BCLINews ReleaseROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI
2023-10-04 00:31U:BCLINews ReleaseBCLI INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI
2023-10-01 16:01U:BCLINews ReleaseBCLI INVESTOR NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - BCLI
2023-09-27 22:48U:BCLINews ReleaseBrainStorm Cell Therapeutics Provides Update on FDA Advisory Committee Meeting to Review NurOwn for the Treatment of ALS
2023-09-27 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Stock Trading Halted Today
2023-08-14 07:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-07 16:05U:BCLINews ReleaseBrainStorm to Announce Second Quarter 2023 Financial Results and Provide a Corporate Update
2023-07-17 09:15U:BCLINews ReleaseBrainstorm Cell Therapeutics Announces Pricing of $7.5 Million Registered Direct Offering
2023-07-12 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
2023-07-07 07:03U:BCLINews ReleaseBrainStorm Cell Therapeutics Data Show Treatment with NurOwn Significantly Reduces NfL, a Key Biomarker of Neurodegeneration
2023-06-20 09:06U:BCLINews ReleaseBrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair
2023-06-16 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference
2023-06-06 06:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn ‚ ® Biologics License Application Scheduled for September 27, 2023
2023-05-19 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit
2023-05-15 07:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-09 06:00U:BCLINews ReleaseBrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update